Activity of anidulafungin in a murine model of Candida krusei infection: evaluation of mortality and disease burden by quantitative tissue cultures and measurement of serum (1,3)-beta-D-glucan levels

Antimicrob Agents Chemother. 2009 Apr;53(4):1639-41. doi: 10.1128/AAC.00955-08. Epub 2009 Jan 12.

Abstract

Experience with anidulafungin against Candida krusei is limited. Immunosuppressed mice were injected with 1.3 x 10(7) to 1.5 x 10(7) CFU of C. krusei. Animals were treated with saline, 40 mg/kg fluconazole, 1 mg/kg amphotericin B, or 10 and 20 mg/kg anidulafungin for 5 days. Anidulafungin improved survival and significantly reduced the number of CFU/g in kidneys and serum beta-glucan levels.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anidulafungin
  • Animals
  • Antifungal Agents / therapeutic use*
  • Candida / isolation & purification*
  • Candidiasis / blood
  • Candidiasis / drug therapy*
  • Candidiasis / microbiology
  • Candidiasis / mortality
  • Disease Models, Animal
  • Echinocandins / therapeutic use*
  • Kidney / microbiology
  • Male
  • Mice
  • beta-Glucans / blood*

Substances

  • Antifungal Agents
  • Echinocandins
  • beta-Glucans
  • beta-1,3-glucan
  • Anidulafungin